Psychiatrists say that research into medications to treat mental health disorders, which affect almost a quarter of the US population, has slowed as major pharmaceutical companies cut back investment in this area. "The companies seem to have concluded that developing new psychiatric drugs is too risky and too expensive," said Richard Friedman, professor of clinical psychiatry at Weill Cornell Medical College in New York. The pullback came after a series ...
Read More
No comments:
Post a Comment